MedPath
Found 2 clinical trials|View Analysis
Sort by:

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

Phase 1
Completed
Conditions
Childhood Solid Tumors
Interventions
First Posted Date
2015-03-19
Last Posted Date
2021-02-09
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
43
Registration Number
NCT02392793
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Phase 2
Recruiting
Conditions
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
Breast Neoplasms
Breast Tumors
HER2-positive Breast Cancer
Hormone Receptor Negative Tumor
Breast Cancer
Early-stage Breast Cancer
Interventions
First Posted Date
2010-01-05
Last Posted Date
2024-10-22
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
5000
Registration Number
NCT01042379
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

University of Texas, Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

University of Kansas, Westwood, Kansas, United States

and more 33 locations
© Copyright 2025. All Rights Reserved by MedPath